Search company, investor...

Neuracle Science

Founded Year



Series C | Alive

Total Raised




Last Raised

$5.42M | 8 mos ago

About Neuracle Science

Neuracle Science develops treatments for neurodegenerative disorders including Alzheimer's disease, neuropathic pain, ALS, and schizophrenia. The company provides a foundation for disease-modifying treatments for neurodegenerative diseases, discovering gene/protein targets with unknown significance using non-biased studies. It was founded in 2015 and is based in Seoul, South Korea.

Headquarters Location

Research and Business Building 406, Science Campus, Korea University 145, Anam-ro, Seongbuk-gu

Seoul, 02841,

South Korea

+82 02 6949 0409

Missing: Neuracle Science's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Neuracle Science's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Neuracle Science

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Neuracle Science is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Neuracle Science Patents

Neuracle Science has filed 20 patents.

The 3 most popular patent topics include:

  • Human proteins
  • Chromosomes (human)
  • Immunology
patents chart

Application Date

Grant Date


Related Topics




Immunology, Chromosomes (human), Immune system, Human proteins, Autoimmune diseases


Application Date


Grant Date



Related Topics

Immunology, Chromosomes (human), Immune system, Human proteins, Autoimmune diseases



Latest Neuracle Science News

CJ Healthcare invests W2b in Alzheimer’s disease drug developer

Jul 2, 2019

PUBLISHED :March 07, 2017 - 15:50 UPDATED :March 07, 2017 - 15:50 [THE INVESTOR]  CJ Healthcare, the pharmaceutical unit of CJ Group, said on March 7 that it has made investment in a Korean biotech startup developing treatments for dementia. CJ Healthcare will invest 2 billion won (US$1.74 million) in Neuracle Science, which is working on Alzheimer’s treatment developing projects, as a part of its 15.2 billion won worth venture capital fund it set up with Timewise Investment, CJ Group’s investment affiliate. This fund, run by Timewise Investment, was formed to create an industry ecosystem where pharmaceutical companies and startups can co-exist, and to establish pharmaceutical direct investment funds and promote open innovation,” CJ Healthcare said in a press release. Neuracle Science is seeking to discover the lead antibody which inhibits a factor of reactive gliosis caused by nerve damage or degenerative brain diseases. The company is currently working on the selection of potential cancer drug target candidates through preclinical animal studies and expects to start clinical trials by 2019. So far, it has confirmed the involvement of gliosis in Alzheimer’s disease mice model over normal mice model and also confirmed considerable reducing of gliosis in Alzheimer’s disease mice model with injection of monoclonal lead antibody that specifically neutralizes the gliosis-inducing novel ligand. Last year, the project by Neuracle Science was also backed by the Korea Drug Development Fund, a government-initiated drug development program by a consortium of health care related Korean ministries. By Park Han-na (

Neuracle Science Frequently Asked Questions (FAQ)

  • When was Neuracle Science founded?

    Neuracle Science was founded in 2015.

  • Where is Neuracle Science's headquarters?

    Neuracle Science's headquarters is located at Research and Business Building 406, Science Campus, Korea University, Seoul.

  • What is Neuracle Science's latest funding round?

    Neuracle Science's latest funding round is Series C.

  • How much did Neuracle Science raise?

    Neuracle Science raised a total of $49.5M.

  • Who are the investors of Neuracle Science?

    Investors of Neuracle Science include Ryukyung PSG Asset Management, QUAD Investment Management, Arche Investment, IBK Capital, Shinhan Investment Corp. and 11 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.